Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RLAY
stocks logo

RLAY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.447
-0.62%
--
--
-0.417
-9.24%
--
--
-0.425
+3.66%
Estimates Revision
The market is revising Downward the revenue expectations for Relay Therapeutics, Inc. (RLAY) for FY2025, with the revenue forecasts being adjusted by -0.49% over the past three months. During the same period, the stock price has changed by 94.17%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+9.03%
In Past 3 Month
Stock Price
Go Up
up Image
+94.17%
In Past 3 Month
Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 15.25 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 15.25 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.000
sliders
Low
14.00
Averages
15.25
High
17.00
Current: 8.000
sliders
Low
14.00
Averages
15.25
High
17.00
Guggenheim
Brad Canino
initiated
$10 -> $15
2025-09-04
Reason
Guggenheim
Brad Canino
Price Target
$10 -> $15
2025-09-04
initiated
Reason
Guggenheim analyst Brad Canino assumed coverage of Relay Therapeutics with a Buy rating and price target of $15, up from $10. The analyst names Relay a "best idea." The firm has high conviction in the company's breast cancer potential and says it could undergo a nearer-term turnaround for the recently initiated development of RLY-2608 for vascular malformations. The company's mutant-selective inhibitor could deliver substantial cross-trial increases in efficacy based, the analyst tells investors in a research note.
Guggenheim
NULL -> Buy
upgrade
$10 -> $15
2025-09-03
Reason
Guggenheim
Price Target
$10 -> $15
2025-09-03
upgrade
NULL -> Buy
Reason
Guggenheim assumed coverage of Relay Therapeutics with a Buy rating and price target of $15, up from $10.
H.C. Wainwright
Robert Burns
Buy
downgrade
$16 -> $14
2025-08-26
Reason
H.C. Wainwright
Robert Burns
Price Target
$16 -> $14
2025-08-26
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Relay Therapeutics to $14 from $16 and keeps a Buy rating on the shares. The firm updated the company's model post the Q2 report.
Raymond James
Strong Buy
downgrade
$29 -> $19
2025-08-08
Reason
Raymond James
Price Target
$29 -> $19
2025-08-08
downgrade
Strong Buy
Reason
Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29 and keeps a Strong Buy rating on the shares. Relay Therapeutics reported Q2 results, and OpEx was down 16% quarter over quarter following strategic cost-cutting initiatives, which is meaningful, the analyst tells investors in a research note. The firm does not anticipate a significant increase in burn in the near-term, despite ramping the Phase 3 RLY-2608 study.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$16
2025-03-07
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$16
2025-03-07
Reiterates
Strong Buy
Reason
Stifel
Bradley Canino
Strong Buy
Maintains
$27 → $23
2025-02-27
Reason
Stifel
Bradley Canino
Price Target
$27 → $23
2025-02-27
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is -4.84, compared to its 5-year average forward P/E of -6.51. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.51
Current PE
-4.84
Overvalued PE
-0.62
Undervalued PE
-12.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.85
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.81
Undervalued EV/EBITDA
-8.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
938.52
Current PS
0.00
Overvalued PS
2202.97
Undervalued PS
-325.93
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 352.49% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RLAY News & Events

Events Timeline

(ET)
2025-11-06
16:56:39
Relay Therapeutics announces Q3 earnings per share of 43 cents, surpassing consensus estimate of 42 cents.
select
2025-08-07 (ET)
2025-08-07
17:53:27
Relay Therapeutics reports Q2 EPS (41c), consensus (47c)
select
2025-07-28 (ET)
2025-07-28
09:50:35
Relay Therapeutics has positive read from Celcuity data, says Barclays
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03NASDAQ.COM
Relay Therapeutics Shares Surge 60% Over the Past Year as an Investor Acquires Nearly 4 Million Additional Shares

  • Commodore Capital's Investment: Commodore Capital increased its stake in Relay Therapeutics (NASDAQ: RLAY) by 3.65 million shares in Q3, bringing its total holdings to 17 million shares valued at $88.7 million, which represents 4.3% of its U.S. equity AUM.

  • Relay Therapeutics Performance: Relay Therapeutics shares have risen 60% over the past year, although they remain nearly 90% below their 2021 highs, highlighting the volatility in early-stage biotech investments.

  • Company Developments: Relay Therapeutics is focused on developing precision small molecule therapeutics for specific cancers and has made progress in clinical trials while reducing its quarterly net loss and managing expenses effectively.

  • Market Outlook: The company's improving financial position and ongoing clinical trials are attracting renewed institutional interest, raising questions about its ability to convert pipeline potential into sustainable value for long-term investors.

[object Object]
Preview
2.0
11-25Benzinga
Major Stocks Including Alibaba, Oscar Health, Ondas Holdings, Lumentum, and Tesla Rise on Monday

  • U.S. Stock Market Performance: U.S. stocks rose on Monday, with the Dow Jones increasing by approximately 250 points, driven by significant gains in various companies.

  • Alibaba's App Success: Alibaba Group's shares surged 4.7% after the company announced its new AI assistant app, Qianwen, reached 10 million downloads within a week of its launch in China.

  • Notable Stock Gains: Several companies saw substantial stock increases, including Inspire Medical Systems (up 28.6%), Oscar Health (up 23.3%), and Ondas Holdings (up 20.2%), among others.

  • Analyst Upgrades and Market Reactions: Stocks like Cipher Mining and Lumentum Holdings experienced gains following analyst upgrades, reflecting positive market sentiment and investor interest in tech and healthcare sectors.

[object Object]
Preview
8.0
11-18NASDAQ.COM
Purchase Relay Therapeutics for $5 and Achieve 22.4% Annualized Returns Through Options

  • Put Selling and Upside Potential: Selling a put option on Relay Therapeutics Inc does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which depends on the stock price falling below the strike price.

  • Counterparty Risk and Myths: The article discusses common myths about options, including counterparty risk, emphasizing that the put seller's only benefit is the premium collected unless the stock price declines significantly.

  • Volatility and Trading History: The historical volatility of Relay Therapeutics Inc is noted to be 75%, and the article suggests using this information alongside fundamental analysis to evaluate the risk-reward of selling a put option at a $5 strike price.

  • Investment Considerations: The potential annualized return of 22.4% from selling the put option is highlighted, but investors should consider the risks involved, particularly in relation to the stock's trading history and volatility.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Relay Therapeutics Inc (RLAY) stock price today?

The current price of RLAY is 8 USD — it has increased 2.17 % in the last trading day.

arrow icon

What is Relay Therapeutics Inc (RLAY)'s business?

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

arrow icon

What is the price predicton of RLAY Stock?

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 15.25 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

Relay Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

Relay Therapeutics Inc. EPS for the last quarter amounts to -0.43 USD, decreased -31.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for Relay Therapeutics Inc (RLAY)'s fundamentals?

The market is revising Downward the revenue expectations for Relay Therapeutics, Inc. (RLAY) for FY2025, with the revenue forecasts being adjusted by -0.49% over the past three months. During the same period, the stock price has changed by 94.17%.
arrow icon

How many employees does Relay Therapeutics Inc (RLAY). have?

Relay Therapeutics Inc (RLAY) has 261 emplpoyees as of December 05 2025.

arrow icon

What is Relay Therapeutics Inc (RLAY) market cap?

Today RLAY has the market capitalization of 1.39B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free